This study is looking at whether certain enzymes, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), can be found in the brains of people with Major Depressive Disorder (MDD) who are experiencing a major depressive episode. Researchers will use special scans called PET scans after injecting two different drugs, 11C-MCI and 11CPS13. The goal is to see if COX-1 and COX-2 levels are higher in people with MDD compared to healthy volunteers. You might be able to join if you are 18-70 years old and have MDD, or if you are a healthy volunteer in the same age range. The study aims to measure the concentration of these drugs in your brain over 36 months. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 64 participants, including those with MDD and healthy volunteers. It is not randomized or placebo-controlled.

What's involved

Participants with MDD will receive 11C-MCI before and after taking celecoxib, followed by PET scans. The study will measure drug concentrations over 36 months.

Compensation

Not stated in the trial record.

Follow-up

The concentration of radioligands will be measured at 36 months after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.